Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate‐Lowering Response—In Search of a Minimum Effective Oxypurinol Concentration [PDF]
Clinical and Translational Science, 2020 The aims of this study were to determine factors that predict serum urate (SU) lowering response to allopurinol and the conversion of allopurinol to oxypurinol, and to determine a minimum therapeutic oxypurinol concentration.
Lisa K. Stamp +8 more
doaj +4 more sources
Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia. [PDF]
PLoS ONE, 2012 Cancer cachexia is a wasting condition, driven by systemic inflammation and oxidative stress. This study investigated eicosapentaenoic acid (EPA) in combination with oxypurinol as a treatment in a mouse model of cancer cachexia. Mice with cancer cachexia
Vanessa C Vaughan +4 more
doaj +4 more sources
Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. [PDF]
Journal of the American College of Cardiology, 2008 OBJECTIVES: This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical ...
Brown, Joanne, BSc +9 more
core +5 more sources
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics
Clinical and Translational Science, 2023 The genetic determinants of the allopurinol dose‐concentration relationship have not been extensively studied. We aimed to clarify what factors, including genetic variation in urate transporters, influence oxypurinol pharmacokinetics (PKs).
Hailemichael Z. Hishe +6 more
doaj +3 more sources
The population pharmacokinetics of allopurinol and oxypurinol in patients with gout
European Journal of Clinical Pharmacology, 2020 Purpose: The aims of this study were to develop a population pharmacokinetic model for allopurinol and oxypurinol and to explore the influence of patient characteristics on allopurinol and oxypurinol pharmacokinetics.
Duffull, SB +5 more
core +3 more sources
Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics [PDF]
Clinical and Translational Science, 2021 The missense variant, breast cancer resistance protein (BCRP) p.Q141K, which encodes a reduced function BCRP, has been linked to poor response to allopurinol.
Bianca Vora +6 more
doaj +2 more sources
PLoS ONE, 2019 A fixed dose combination of lesinurad and allopurinol has been recently approved by USFDA and EMA for treatment of gout-associated hyperuricemia in patients who have not achieved target serum uric acid levels with allopurinol alone.
Muzaffar Iqbal +3 more
doaj +2 more sources
Journal of Pharmaceutical Analysis, 2017 The present study describes a simple, reliable and reproducible liquid chromatography–tandem mass spectrometry method (LC–MS/MS) for the simultaneous determination of allopurinol and its active metabolite, oxypurinol in human plasma for a pharmacokinetic/
Dhiraj M. Rathod +5 more
doaj +2 more sources
Oxypurinol protects renal ischemia/reperfusion injury via heme oxygenase-1 induction
Frontiers in Medicine, 2023 Renal ischemia/reperfusion (I/R) injury is a major cause of acute kidney injury (AKI) by increasing oxidative stress, inflammatory responses, and tubular cell death.
Hye Bin Kang +3 more
doaj +1 more source
An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites
Clinical and Translational Science, 2022 ABCG2 is a gene that codes for the human breast cancer resistance protein (BCRP). It is established that rs2231142 G>T, a single nucleotide polymorphism of the ABCG2 gene, is associated with gout and poor response to allopurinol, a uric acid‐lowering ...
Marc‐Olivier Pilon +11 more
doaj +1 more source